{"title": "Investigating the Impact of Asymptomatic Carriers on COVID-19 Transmission", "doi": "10.1101/2020.03.18.20037994", "citation_id": "2020.03.18.20037994v1", "date": "2020-03-20", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.18.20037994", "abstract": "<p>Coronavirus disease 2019 (COVID-19) is a novel human respiratory disease caused by the SARS-CoV-2 virus. Asymptomatic individuals in the context of COVID-19 are those subjects who are carriers of the virus but display no clinical symptoms. Current evidence reveals that this sub-population is a major contributing factor in the propagation of this disease, while escaping detection by public health surveillance systems. In this manuscript, we present a mathematical model taking into account asymptomatic carriers. Our results indicate a basic reproduction number as high as 26.5. The first three weeks of the model exhibit exponential growth, which is in agreement with average case data collected from thirteen countries with universal health care and robust communicable disease surveillance systems; the average rate of growth in the number of reported cases is 25\\% per day during this period. The model was applied to every county in the US to give estimates of mild, severe, and critical case severity, and also mortality. These estimates can be considered an upper bound.</p>", "twitter_description": "Coronavirus disease 2019 (COVID-19) is a novel human respiratory disease caused by the SARS-CoV-2 virus. Asymptomatic individuals in the context of COVID-19 are those subjects who are carriers of the virus but display no clinical symptoms. Current evidence reveals that this sub-population is a major contributing factor in the propagation of this disease, while escaping detection by public health surveillance systems. In this manuscript, we present a mathematical model taking into account asymptomatic carriers. Our results indicate a basic reproduction number as high as 26.5. The first three weeks of the model exhibit exponential growth, which is in agreement with average case data collected from thirteen countries with universal health care and robust communicable disease surveillance systems; the average rate of growth in the number of reported cases is 25\\% per day during this period. The model was applied to every county in the US to give estimates of mild, severe, and critical case severity, and also mortality. These estimates can be considered an upper bound.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nN/A\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data used in this article is available from public sources.\n\n<https://tinyurl.com/USA-COVID-19-Cases>\n\n<https://drive.google.com/open?id=18qaRKnQG1GoXamnzJwkHu2GG9xCe4w8_>", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20037994v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20037994v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.18.20037994v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.18.20037994.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.18.20037994v1", "access_rights": "restricted", "authors": ["Jacob B Aguilar", "Juan B. Gutierrez"]}